Taro Pharmaceutical Industries Ltd. (NYSE: TARO) Stock Competitors & Peer Comparison

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while TAK trades at $17.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TAK's P/E ratio is 12.55. In terms of profitability, TARO's ROE is +0.03%, compared to TAK's ROE of +0.02%. Regarding short-term risk, TARO is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for TARO.Check TAK's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while HLN trades at $10.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HLN's P/E ratio is 25.11. In terms of profitability, TARO's ROE is +0.03%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TARO is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for TARO.Check HLN's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while TEVA trades at $35.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TEVA's P/E ratio is 12.06. In terms of profitability, TARO's ROE is +0.03%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, TARO is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for TARO.Check TEVA's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while VTRS trades at $16.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas VTRS's P/E ratio is 6.52. In terms of profitability, TARO's ROE is +0.03%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TARO is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TARO.Check VTRS's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TARO's ROE is +0.03%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TARO is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TARO.Check ITCI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TARO's ROE is +0.03%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TARO is similarly volatile compared to CTLT. This indicates similar risk in terms of short-term price fluctuations for TARO.Check CTLT's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ELAN trades at $22.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ELAN's P/E ratio is 20.86. In terms of profitability, TARO's ROE is +0.03%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TARO is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ELAN's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while RDY trades at $12.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RDY's P/E ratio is 20.01. In terms of profitability, TARO's ROE is +0.03%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TARO is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for TARO.Check RDY's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while LNTH trades at $100.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LNTH's P/E ratio is 16.97. In terms of profitability, TARO's ROE is +0.03%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TARO is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for TARO.Check LNTH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while AMRX trades at $18.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AMRX's P/E ratio is 20.16. In terms of profitability, TARO's ROE is +0.03%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TARO is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for TARO.Check AMRX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while INDV trades at $38.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas INDV's P/E ratio is 10.64. In terms of profitability, TARO's ROE is +0.03%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TARO is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for TARO.Check INDV's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while SUPN trades at $47.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SUPN's P/E ratio is 15.57. In terms of profitability, TARO's ROE is +0.03%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TARO is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TARO.Check SUPN's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while RGC trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RGC's P/E ratio is -380.99. In terms of profitability, TARO's ROE is +0.03%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TARO is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check RGC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while BHC trades at $6.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BHC's P/E ratio is 1.59. In terms of profitability, TARO's ROE is +0.03%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TARO is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check BHC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TARO's ROE is +0.03%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TARO is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for TARO.Check DCPH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while HCM trades at $12.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HCM's P/E ratio is 4.69. In terms of profitability, TARO's ROE is +0.03%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TARO is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TARO.Check HCM's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TARO's ROE is +0.03%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, TARO is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TARO.Check AVDL's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TARO's ROE is +0.03%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TARO is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TARO.Check EMBCV's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TARO's ROE is +0.03%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, TARO is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TARO.Check DVAX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ANIP trades at $78.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ANIP's P/E ratio is 9.52. In terms of profitability, TARO's ROE is +0.03%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TARO is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ANIP's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while PRGO trades at $12.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PRGO's P/E ratio is 5.13. In terms of profitability, TARO's ROE is +0.03%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TARO is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TARO.Check PRGO's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while HROW trades at $40.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HROW's P/E ratio is 449.33. In terms of profitability, TARO's ROE is +0.03%, compared to HROW's ROE of -0.34%. Regarding short-term risk, TARO is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TARO.Check HROW's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while PAHC trades at $34.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PAHC's P/E ratio is 11.70. In terms of profitability, TARO's ROE is +0.03%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TARO is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check PAHC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ALVO trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ALVO's P/E ratio is -11.21. In terms of profitability, TARO's ROE is +0.03%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, TARO is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ALVO's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ETON trades at $44.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ETON's P/E ratio is -637.14. In terms of profitability, TARO's ROE is +0.03%, compared to ETON's ROE of -0.06%. Regarding short-term risk, TARO is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ETON's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CRON trades at $3.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CRON's P/E ratio is 29.44. In terms of profitability, TARO's ROE is +0.03%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TARO is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TARO.Check CRON's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while PCRX trades at $25.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PCRX's P/E ratio is 9.62. In terms of profitability, TARO's ROE is +0.03%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TARO is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for TARO.Check PCRX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while COLL trades at $29.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas COLL's P/E ratio is 3.70. In terms of profitability, TARO's ROE is +0.03%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TARO is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TARO.Check COLL's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TARO's ROE is +0.03%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TARO is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TARO.Check PETQ's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while AMPH trades at $20.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AMPH's P/E ratio is 7.09. In terms of profitability, TARO's ROE is +0.03%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TARO is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TARO.Check AMPH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while IRWD trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas IRWD's P/E ratio is 5.54. In terms of profitability, TARO's ROE is +0.03%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TARO is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TARO.Check IRWD's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while EVO trades at $2.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EVO's P/E ratio is -2.82. In terms of profitability, TARO's ROE is +0.03%, compared to EVO's ROE of -0.24%. Regarding short-term risk, TARO is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for TARO.Check EVO's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TARO's ROE is +0.03%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TARO is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for TARO.Check BDSI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while TLRY trades at $4.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TLRY's P/E ratio is -7.21. In terms of profitability, TARO's ROE is +0.03%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, TARO is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TARO.Check TLRY's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while EOLS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EOLS's P/E ratio is -24.04. In terms of profitability, TARO's ROE is +0.03%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TARO is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TARO.Check EOLS's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while AQST trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AQST's P/E ratio is -6.46. In terms of profitability, TARO's ROE is +0.03%, compared to AQST's ROE of +1.91%. Regarding short-term risk, TARO is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TARO.Check AQST's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while KMDA trades at $7.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas KMDA's P/E ratio is 20.77. In terms of profitability, TARO's ROE is +0.03%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TARO is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for TARO.Check KMDA's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CGC trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CGC's P/E ratio is -0.58. In terms of profitability, TARO's ROE is +0.03%, compared to CGC's ROE of -0.31%. Regarding short-term risk, TARO is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check CGC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while TKNO trades at $6.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TKNO's P/E ratio is -20.84. In terms of profitability, TARO's ROE is +0.03%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TARO is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TARO.Check TKNO's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TARO's ROE is +0.03%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TARO is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ALIM's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TARO's ROE is +0.03%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TARO is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check LNDC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while EMBC trades at $4.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EMBC's P/E ratio is 1.70. In terms of profitability, TARO's ROE is +0.03%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, TARO is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check EMBC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ORGO trades at $1.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ORGO's P/E ratio is 62.00. In terms of profitability, TARO's ROE is +0.03%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, TARO is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ORGO's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TARO's ROE is +0.03%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TARO is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TARO.Check TYHT's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while SIGA trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SIGA's P/E ratio is 11.30. In terms of profitability, TARO's ROE is +0.03%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TARO is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TARO.Check SIGA's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while LFCR trades at $5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LFCR's P/E ratio is -4.68. In terms of profitability, TARO's ROE is +0.03%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, TARO is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for TARO.Check LFCR's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ACB trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ACB's P/E ratio is -6.10. In terms of profitability, TARO's ROE is +0.03%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TARO is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ACB's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas REPH's P/E ratio is -8.04. In terms of profitability, TARO's ROE is +0.03%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TARO is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TARO.Check REPH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while DERM trades at $6.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DERM's P/E ratio is -17.38. In terms of profitability, TARO's ROE is +0.03%, compared to DERM's ROE of -0.36%. Regarding short-term risk, TARO is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TARO.Check DERM's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CRDL trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CRDL's P/E ratio is -5.05. In terms of profitability, TARO's ROE is +0.03%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, TARO is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TARO.Check CRDL's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas THTX's P/E ratio is -28.83. In terms of profitability, TARO's ROE is +0.03%, compared to THTX's ROE of +0.17%. Regarding short-term risk, TARO is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for TARO.Check THTX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TARO's ROE is +0.03%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TARO is similarly volatile compared to ASRT. This indicates similar risk in terms of short-term price fluctuations for TARO.Check ASRT's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while OGI trades at $0.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas OGI's P/E ratio is -3.81. In terms of profitability, TARO's ROE is +0.03%, compared to OGI's ROE of -0.07%. Regarding short-term risk, TARO is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TARO.Check OGI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CPIX trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CPIX's P/E ratio is -19.50. In terms of profitability, TARO's ROE is +0.03%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TARO is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TARO.Check CPIX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TARO's ROE is +0.03%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TARO is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for TARO.Check SCTL's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PROC's P/E ratio is 1.53. In terms of profitability, TARO's ROE is +0.03%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TARO is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TARO.Check PROC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TARO's ROE is +0.03%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TARO is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TARO.Check OPTN's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TARO's ROE is +0.03%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TARO is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ZOM's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ZYBT trades at $1.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, TARO's ROE is +0.03%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, TARO is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ZYBT's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TARO's ROE is +0.03%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, TARO is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TARO.Check GRVI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TARO's ROE is +0.03%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TARO is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ZYNE's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TARO's ROE is +0.03%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TARO is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check SSIC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TARO's ROE is +0.03%, compared to VLNS's ROE of N/A. Regarding short-term risk, TARO is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TARO.Check VLNS's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while BGM trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BGM's P/E ratio is -1.04. In terms of profitability, TARO's ROE is +0.03%, compared to BGM's ROE of -0.07%. Regarding short-term risk, TARO is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TARO.Check BGM's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TARO's ROE is +0.03%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, TARO is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TARO.Check DRRX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while INCR trades at $0.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas INCR's P/E ratio is -2.26. In terms of profitability, TARO's ROE is +0.03%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TARO is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for TARO.Check INCR's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TARO's ROE is +0.03%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, TARO is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TARO.Check JUPW's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas QLI's P/E ratio is -4.92. In terms of profitability, TARO's ROE is +0.03%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TARO is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TARO.Check QLI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TARO's ROE is +0.03%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TARO is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TARO.Check HEXO's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while TLPH trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TLPH's P/E ratio is -4.61. In terms of profitability, TARO's ROE is +0.03%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, TARO is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TARO.Check TLPH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while RMTI trades at $7.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RMTI's P/E ratio is -6.89. In terms of profitability, TARO's ROE is +0.03%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, TARO is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TARO.Check RMTI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while AYTU trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AYTU's P/E ratio is -1.23. In terms of profitability, TARO's ROE is +0.03%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, TARO is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TARO.Check AYTU's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while TXMD trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas TXMD's P/E ratio is 105.45. In terms of profitability, TARO's ROE is +0.03%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, TARO is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for TARO.Check TXMD's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TARO's ROE is +0.03%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TARO is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TARO.Check CYTH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TARO's ROE is +0.03%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, TARO is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TARO.Check EVOK's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, TARO's ROE is +0.03%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, TARO is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for TARO.Check BFRIW's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while OPTH trades at $5.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas OPTH's P/E ratio is -18.56. In terms of profitability, TARO's ROE is +0.03%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, TARO is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TARO.Check OPTH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TARO's ROE is +0.03%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, TARO is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ACRX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while COSM trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas COSM's P/E ratio is -0.38. In terms of profitability, TARO's ROE is +0.03%, compared to COSM's ROE of -0.96%. Regarding short-term risk, TARO is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for TARO.Check COSM's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TARO's ROE is +0.03%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TARO is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TARO.Check AGRX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TARO's ROE is +0.03%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, TARO is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TARO.Check NLTX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LCI's P/E ratio is -0.04. In terms of profitability, TARO's ROE is +0.03%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TARO is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TARO.Check LCI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TARO's ROE is +0.03%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TARO is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TARO.Check ADMP's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while YCBD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas YCBD's P/E ratio is -1.38. In terms of profitability, TARO's ROE is +0.03%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TARO is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TARO.Check YCBD's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while GELS trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas GELS's P/E ratio is -1.09. In terms of profitability, TARO's ROE is +0.03%, compared to GELS's ROE of -0.25%. Regarding short-term risk, TARO is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TARO.Check GELS's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas MNK's P/E ratio is -0.44. In terms of profitability, TARO's ROE is +0.03%, compared to MNK's ROE of -0.26%. Regarding short-term risk, TARO is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TARO.Check MNK's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TARO's ROE is +0.03%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TARO is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check FLGC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CPHI trades at $1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CPHI's P/E ratio is -1.76. In terms of profitability, TARO's ROE is +0.03%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, TARO is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TARO.Check CPHI's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while UPC trades at $5.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas UPC's P/E ratio is -0.69. In terms of profitability, TARO's ROE is +0.03%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TARO is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TARO.Check UPC's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while SBFM trades at $1.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SBFM's P/E ratio is -0.20. In terms of profitability, TARO's ROE is +0.03%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, TARO is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for TARO.Check SBFM's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while SHPH trades at $4.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SHPH's P/E ratio is -0.20. In terms of profitability, TARO's ROE is +0.03%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, TARO is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TARO.Check SHPH's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TARO's ROE is +0.03%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TARO is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TARO.Check PLXP's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while SNOA trades at $1.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas SNOA's P/E ratio is -1.22. In terms of profitability, TARO's ROE is +0.03%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TARO is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TARO.Check SNOA's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TARO's ROE is +0.03%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TARO is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TARO.Check ATNX's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas PROCW's P/E ratio is N/A. In terms of profitability, TARO's ROE is +0.03%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, TARO is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for TARO.Check PROCW's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while RDHL trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas RDHL's P/E ratio is 0.12. In terms of profitability, TARO's ROE is +0.03%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, TARO is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for TARO.Check RDHL's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, TARO's ROE is +0.03%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, TARO is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for TARO.Check YCBD-PA's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas CYTHW's P/E ratio is N/A. In terms of profitability, TARO's ROE is +0.03%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, TARO is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for TARO.Check CYTHW's competition here

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TARO stands at 1.6B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, TARO is priced at $42.98 on the NYSE, while LSDI trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TARO currently has a P/E ratio of 30.05, whereas LSDI's P/E ratio is -0.07. In terms of profitability, TARO's ROE is +0.03%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, TARO is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for TARO.Check LSDI's competition here